Warner-Lambert v Actavis ‘disappointing’ for innovators: lawyers

15-11-2018

Warner-Lambert v Actavis ‘disappointing’ for innovators: lawyers

Dmitrii_Guzhanin / iStockphoto.com

The UK Supreme Court’s decision in Warner-Lambert v Actavis is disappointing for pharmaceutical innovators, and enforcing second medical use patents may now be more challenging, lawyers have told LSIPR.


Warner-Lambert, Pfizer, Actavis, Mylan, UK Supreme Court, pregabalin, Lyrica, second medical use patent, plausibility, sufficiency, pain treatment, patent

LSIPR